HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is ple
TORONTO--(BUSINESS WIRE)--Novel Biotechnology Inc., an innovative biotechnology start-up headquartered in Canada, is pleased to announce the successful completion of its $2.5 million seed round funding. This significant milestone was achieved with the sup
Collaboration will support rapid evidence generation for clinical developmentPALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service, today announced an ag
Co-founder, Gilly Regev, to lead Strategy and Innovation at SaNOtizeVANCOUVER, British Columbia--(BUSINESS WIRE)--SaNOtize Research and Development Corp. (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, today announced that the c
First clinical data from a pan-coronavirus vaccine candidate Elicited high and sustained neutralizing responses against a panel of COVID-19 variants, including Wuhan, Delta, Beta, Omicron BA.5, as well as multiple animal coronaviruses including bat and
- Cybin to acquire Small Pharma Inc. in a previously announced all-share transaction expected to close in Q4 2023, creating an international clinical-stage leader in novel psychedelic therapeutics with the largest IP portfolio in the sector - - Results s
Recently announced Funding Commitment from U.S. Air Force is expected to advance ATI-1701 Biodefense Vaccine Candidate to INDHALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological
Company’s unique AI foundation model BigRNA is the first transformer neural network for the discovery of RNA biology and therapeutics Represents a new generation of deep learning AI that can be applied to a range of different RNA therapeutic discovery
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.